Nick Leschly, bluebird CEO at JPM20 (Jeff Rumans)
Bluebird takes $200M payout from Bristol Myers as Covid-19, BLA delays force execs to bring out the budget ax
Covid-19 is taking its toll on one of the industry’s flashiest biotechs.
In their Q1 filing, bluebird bio disclosed a series of changes designed to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
